Crowley has been appointed to the newly created role of senior VP, growth. The announcement continues the agency’s positive momentum as it solidifies its strong leadership bench.
Lilly said it expects the drugs to remain in tight supply, but plans for significant production increases in the second half of the year.
The solution designed to enhance patient affordability and medication adherence by reaching the most influential stakeholder in health care – the healthcare professional, who lacks awareness of Patient affordability programs. Co-Pay Spark empowers HCPs to ignite awareness of and access to assistance programs for the patients who need them most, ultimately leading to improved adherence and better health outcomes.
Based on strong overall and progression-free survival data in its Phase III confirmatory study, Pfizer and Genmab’s antibody-drug conjugate Tivdak on Monday secured the FDA’s full approval for recurrent or metastatic cervical cancer that had progressed on or after chemotherapy.
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.
Ono Pharmaceutical said Monday it will pay $2.4 billion to acquire Deciphera Pharmaceuticals for cancer drugs that could generate peak annual sales of more than $1 billion.